Cargando…
Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD
BACKGROUND: Use of short-acting β(2)-agonists in chronic obstructive pulmonary disease (COPD) during treatment with long-acting β(2)-agonists is recommended as needed, but its effectiveness is unclear. The purpose of this study was to assess the additional bronchodilating effect of increasing doses...
Autores principales: | La Piana, Giuseppe Emanuele, Corda, Luciano, Bertella, Enrica, Montemurro, Luigi Taranto, Pini, Laura, Tantucci, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157942/ https://www.ncbi.nlm.nih.gov/pubmed/21857779 http://dx.doi.org/10.2147/COPD.S22179 |
Ejemplares similares
-
COPD: it is time to change!
por: Tantucci, Claudio, et al.
Publicado: (2015) -
Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol
por: Bateman, ED, et al.
Publicado: (2006) -
Inhaled Corticosteroids in COPD: Trying to Make a Long Story Short
por: Tantucci, Claudio, et al.
Publicado: (2020) -
The Beta-2-Adrenoreceptor Agonists, Formoterol and Indacaterol, but Not Salbutamol, Effectively Suppress the Reactivity of Human Neutrophils In Vitro
por: Anderson, Ronald, et al.
Publicado: (2014) -
Central airways remodeling in COPD patients
por: Pini, Laura, et al.
Publicado: (2014)